Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Filings indexed 412 across all filing types
Latest filing 2025-08-19 Regulatory Filings
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2025-08-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-19 English
424B3
Regulatory Filings
2025-08-18 English
424B4
Regulatory Filings
2025-08-18 English
Regulatory Filings 2025
Regulatory Filings
2025-08-14 English
Regulatory Filings 2025
Regulatory Filings
2025-08-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.